Promising antileishmanial effectiveness of doxorubicin and Doxil against Leishmania major : An in vitro assay | Zendy

Azar Shokri | Zendy; Javad Akhtari | Zendy; Masoud Keighobadi | Zendy; Mahdi Fakhar | Zendy; Saeed Hosseini Teshnizi | Zendy; Saeed Emami | Zendy; Sajede Sadjjadian | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Promising antileishmanial effectiveness of doxorubicin and Doxil against Leishmania major : An in vitro assay

Author(s) -

Azar Shokri,

Javad Akhtari,

Masoud Keighobadi,

Mahdi Fakhar,

Saeed Hosseini Teshnizi,

Saeed Emami,

Sajede Sadjjadian

Publication year - 2017

Publication title -

asian pacific journal of tropical medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.491

H-Index - 52

ISSN - 1995-7645

DOI - 10.1016/j.apjtm.2016.09.014

Subject(s) - amastigote , cytotoxicity , pharmacology , doxorubicin , ic50 , leishmania , in vitro , leishmania major , macrophage , cell culture , chemistry , biology , biochemistry , chemotherapy , parasite hosting , world wide web , computer science , genetics

To evaluate the effect of doxorubicin and its pegylated liposomal formulation (Doxil, Caelyx) on in vitro susceptibility of promastigote and amastigote stages of Leishmania major.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research